Merkel Cell Carcinoma Market Size, Share, Industry, Forecast and outlook (2023-2030)

Global Merkel Cell Carcinoma Market is segmented By Therapy (Immunotherapy, Radiation therapy, Combination therapies, Others), By Type of Diagnosis (Biopsy test, Positron emission tomography scan, Computerized axial tomography scan, Immunohistochemistry test, Others), By Distribution Channel (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Merkel Cell Carcinoma Market Overview

[200 pages] Report on Global Merkel Cell Carcinoma Market by DataM Intelligence estimates the market to grow at a CAGR of 8.7% during the forecast period 2023-2030. 

Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with a high risk of recurring and spreading throughout the body. Most of the recurrences take place within two years after diagnosis of the primary tumor. Neck dissection is used for the clinically positive nodes, and chemotherapy is given for advanced disease.

Merkel Cell Carcinoma Market Scope and Summary

Merkel Cell Carcinoma Market Trends and Dynamics

The rising prevalence of MCC, increasing demand for immunotherapy treatment, improvement in treatment rates, government initiatives, and innovation of drug therapies with high efficacy. are driving the growth of the market. Innovative animal healthcare products are expected to boost the market over the period forecast.  

The rising prevalence of Merkel cell carcinoma is expected to drive the market growth     

The rising prevalence of Merkel cell carcinoma is one of the dominating factors, propelling the global Merkel cell carcinoma market. According to a report published in the Current Dermatology Reports journal, the estimated annual prevalence of MCC was around 0.6 per 100,000 people. The National Cancer Database has reported that each year around 2500 and 1500, new MCC cases are reported in the European and US region, respectively. The researchers of Fred Hutchison University and the University of Washington in Seattle reported the promising results of a small study combining Avelumab with two other treatments. The combination therapy enhances T cell generation and attacks the MCC cells. The National Cancer Institute has also commenced a clinical trial involving the investigational study of the drug ipilimumab Theatic Merkel cell carcinoma. Curalso recently is in phase 2 clinical study.

Growing research and development activities for the treatment of Merkel cell carcinoma is expected to boost the market. Patients with Merkel cell carcinoma are usually first treated with surgery. Patients with more advanced diseases may receive additional treatments such as radiation and drug therapy after or instead of surgery. Surgery to remove the primary tumor is the most common initial treatment for merkel cell carcinoma. Thus, these factors are driving the growth of the market in the forecast period.

The Side effects of external radiation therapy will hamper the growth of the market   

However, the side effects of external radiation therapy include skin changes, nausea, diarrhoea, fatigue, painful sores in the throat and mouth, and dry mouth or thick saliva. The side effects of the radiation are temporary, but some rare serious side effects can become permanent. In a few cases, radiation to the chest can cause lung damage, which may lead to problems breathing and shortness of breath.

Merkel Cell Carcinoma Market Segmentation Analysis

The radiation therapy segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)          

Radiation therapy is expected to boost the market over the period of forecast, owing to the presence of clinical trials undertaken by the key players. Radiation therapy (also called radiotherapy) is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors. At low doses, radiation is used in x-rays to see the inside body, as with x-rays of teeth or broken bones. Radiation therapy does not kill cancer cells right away. It takes days or weeks of treatment before DNA is damaged enough for cancer cells to die. Then, cancer cells keep dying for weeks or months after radiation therapy ends.

Cancer cells whose DNA is damaged beyond repair stop dividing or die. When the damaged cells die, they are broken down and removed by the body. Radiation therapy does not kill cancer cells right away. It takes days or weeks of treatment before DNA is damaged enough for cancer cells to die. Then, cancer cells keep dying for weeks or months after radiation therapy ends.

Global Merkel Cell Carcinoma Market Geographical Share

The North American region holds the largest market share of the global Merkel cell carcinoma market

North America is expected to contribute a significant market share in the MCC market. This is owing to the increased incidence of MCC, expanding treatment options, and increased advancements in technologies. According to the educational Cancer Database, around 1500 new MCC cases are rep technology advancement rates increased with increasing age among the men and women. They were higher among non-Hispanic whites (2.5/100,000 persons), localized stage (1.2/100,000 persons), and tumors located on the head and neck (0.9/100,000 persons). According to the National organization of rare disorders, the incidence is approximately 0.7 people per 100,000 people in the population of the US. It increases to about 9.8 people per 100,000 in individuals more than 85 years of age. On February 16, 2018, UW Medicine released an article on the projected increase of cases of Merkel cell carcinoma in the US and it showed that the incidence is expected to exceed 3,025 cases by 2025.

The Nain Merkel cell carcinoma cases in the US. The presence of investigational drugs like Pazopanib or imatinib, which are tyrosine kinase inhibitors, has shown some activity against Merkel cell carcinoma. However, more research is required to determine the long-term safety and efficacy of these therapies for Merkel cell carcinoma. For instance, the Patient Advocate Foundation, a non-profit organization has launched funds for MCC patients to help cover the travel costs related to the treatment. Once approved, the financial fund will provide one-time assistance of $450 to cover the transportation-related expenses connected to treatment appointments.

Merkel Cell Carcinoma Market Companies and Competitive Landscape

The Merkel cell carcinoma market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market are Pfizer, Amgen Inc., Merck & Co. Inc, OncoSec Medical Inc., Millennium Pharmaceuticals Inc, and others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Merkel cell carcinoma market globally.

Merck & Co., Inc.

Overview:

Merck & Co., Inc. delivers health solutions via biologic therapies, prescription medicines, vaccines, animal health, and consumer care products. It runs through the following segments: Pharmaceutical, Animal Health, and Other.     

Product Portfolio:

KEYTRUDA: It is an immunotherapy and it works with your immune system to help fight cancer. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to death.

The global Merkel cell carcinoma market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.